Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase 1, Exploratory Study Investigating the Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs HTL 9936 (Primary)
- Indications Cognition disorders
- Focus Therapeutic Use
- Sponsors Heptares Therapeutics
- 02 Feb 2017 Status changed from recruiting to completed.
- 09 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 15 Sep 2015 New trial record